Literature DB >> 25435509

The clinical management of Type 2 Gaucher disease.

Karin Weiss1, Ashley Gonzalez1, Grisel Lopez1, Leah Pedoeim1, Catherine Groden1, Ellen Sidransky1.   

Abstract

Gaucher disease, the inherited deficiency of the enzyme glucocerebrosidase, is the most common of the lysosomal storage disorders. Type 2 Gaucher disease, the most severe and progressive form, manifests either prenatally or in the first months of life, followed by death within the first years of life. The rarity of the many lysosomal storage disorders makes their diagnosis a challenge, especially in the newborn period when the focus is often on more prevalent illnesses. Thus, a heightened awareness of the presentation of these rare diseases is necessary to ensure their timely consideration. This review, designed to serve as a guide to physicians treating newborns and infants with Gaucher disease, discusses the presenting manifestations of Type 2 Gaucher disease, the diagnostic work-up, associated genotypes and suggestions for management. We also address the ethical concerns that may arise with this progressive and lethal disorder, since currently available treatments may prolong life, but do not impact the neurological manifestations of the disease. Published by Elsevier Inc.

Entities:  

Keywords:  Acute neuronopathic; Congenital ichthyosis; Gaucher disease; Hydrops fetalis; Lysosomal storage disorder; Palliative care

Mesh:

Substances:

Year:  2014        PMID: 25435509      PMCID: PMC4312716          DOI: 10.1016/j.ymgme.2014.11.008

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  84 in total

1.  Skin ultrastructural findings in type 2 Gaucher disease: diagnostic implications.

Authors:  Aegean Chan; Walter M Holleran; Tajh Ferguson; Debra Crumrine; Ozlem Goker-Alpan; Raphael Schiffmann; Nahid Tayebi; Edward I Ginns; Peter M Elias; Ellen Sidransky
Journal:  Mol Genet Metab       Date:  2011-09-16       Impact factor: 4.797

2.  Collodion babies with Gaucher's disease.

Authors:  K Lui; C Commens; R Choong; R Jaworski
Journal:  Arch Dis Child       Date:  1988-07       Impact factor: 3.791

3.  Congenital ichthyosis in severe type II Gaucher disease with a homozygous null mutation.

Authors:  Sabine Haverkaemper; Thorsten Marquardt; Ingrid Hausser; Katharina Timme; Thomas Kuehn; Christoph Hertzberg; Rainer Rossi
Journal:  Neonatology       Date:  2011-04-01       Impact factor: 4.035

4.  Convection perfusion of glucocerebrosidase for neuronopathic Gaucher's disease.

Authors:  Russell R Lonser; Stuart Walbridge; Gary J Murray; Michele R Aizenberg; Alexander O Vortmeyer; Johannes M F G Aerts; Roscoe O Brady; Edward H Oldfield
Journal:  Ann Neurol       Date:  2005-04       Impact factor: 10.422

5.  Perinatal and pediatric issues in palliative and end-of-life care from the 2011 Summit on the Science of Compassion.

Authors:  Jonne M Youngblut; Dorothy Brooten
Journal:  Nurs Outlook       Date:  2012-10-01       Impact factor: 3.250

6.  Epidermal abnormalities may distinguish type 2 from type 1 and type 3 of Gaucher disease.

Authors:  E Sidransky; M Fartasch; R E Lee; L A Metlay; S Abella; A Zimran; W Gao; P M Elias; E I Ginns; W M Holleran
Journal:  Pediatr Res       Date:  1996-01       Impact factor: 3.756

Review 7.  Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA).

Authors:  Kathleen S Hruska; Mary E LaMarca; C Ronald Scott; Ellen Sidransky
Journal:  Hum Mutat       Date:  2008-05       Impact factor: 4.878

Review 8.  Occasional seizures, epilepsy, and inborn errors of metabolism.

Authors:  Olivier Dulac; Barbara Plecko; Svetlana Gataullina; Nicole I Wolf
Journal:  Lancet Neurol       Date:  2014-07       Impact factor: 44.182

Review 9.  Gaucher disease: a comprehensive review.

Authors:  Barry E Rosenbloom; Neal J Weinreb
Journal:  Crit Rev Oncog       Date:  2013

Review 10.  Management of common neurologic symptoms in pediatric palliative care: seizures, agitation, and spasticity.

Authors:  Courtney J Wusthoff; Renée A Shellhaas; Daniel J Licht
Journal:  Pediatr Clin North Am       Date:  2007-10       Impact factor: 3.278

View more
  33 in total

1.  Four Gaucher disease type II patients with three novel mutations: a single centre experience from Turkey.

Authors:  Fatma Derya Bulut; Deniz Kör; Berna Şeker-Yılmaz; Özlem Hergüner; Serdar Ceylaner; Ferda Özkınay; Sebile Kılavuz; Neslihan Önenli-Mungan
Journal:  Metab Brain Dis       Date:  2018-04-14       Impact factor: 3.584

Review 2.  Lysosomal storage disease overview.

Authors:  Angela Sun
Journal:  Ann Transl Med       Date:  2018-12

3.  A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism.

Authors:  Elma Aflaki; Daniel K Borger; Nima Moaven; Barbara K Stubblefield; Steven A Rogers; Samarjit Patnaik; Frank J Schoenen; Wendy Westbroek; Wei Zheng; Patricia Sullivan; Hideji Fujiwara; Rohini Sidhu; Zayd M Khaliq; Grisel J Lopez; David S Goldstein; Daniel S Ory; Juan Marugan; Ellen Sidransky
Journal:  J Neurosci       Date:  2016-07-13       Impact factor: 6.167

4.  Premature Identical Twin Neonates With Sleep Apnea.

Authors:  Anirudh Ramesh; Johanna Diaz; Lawrence Nogee; Jessica Duis; Dae Song Jang; Cathleen Lawson; Gustavo Maegawa
Journal:  Clin Pediatr (Phila)       Date:  2017-03-20       Impact factor: 1.168

5.  Recent advances in the diagnosis and management of Gaucher disease.

Authors:  Sam E Gary; Emory Ryan; Alta M Steward; Ellen Sidransky
Journal:  Expert Rev Endocrinol Metab       Date:  2018-03-12

Review 6.  Lysosomal Leukodystrophies Lysosomal Storage Diseases Associated With White Matter Abnormalities.

Authors:  Gustavo H B Maegawa
Journal:  J Child Neurol       Date:  2019-02-13       Impact factor: 1.987

Review 7.  Gaucher disease: Progress and ongoing challenges.

Authors:  Pramod K Mistry; Grisel Lopez; Raphael Schiffmann; Norman W Barton; Neal J Weinreb; Ellen Sidransky
Journal:  Mol Genet Metab       Date:  2016-11-17       Impact factor: 4.797

Review 8.  The Complicated Relationship between Gaucher Disease and Parkinsonism: Insights from a Rare Disease.

Authors:  Elma Aflaki; Wendy Westbroek; Ellen Sidransky
Journal:  Neuron       Date:  2017-02-22       Impact factor: 17.173

Review 9.  In Vivo NMR Studies of the Brain with Hereditary or Acquired Metabolic Disorders.

Authors:  Erica B Sherry; Phil Lee; In-Young Choi
Journal:  Neurochem Res       Date:  2015-11-26       Impact factor: 3.996

10.  The natural history of type 2 Gaucher disease in the 21st century: A retrospective study.

Authors:  Tamanna Roshan Lal; Gurpreet K Seehra; Alta M Steward; Chelsie N Poffenberger; Emory Ryan; Nahid Tayebi; Grisel Lopez; Ellen Sidransky
Journal:  Neurology       Date:  2020-08-06       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.